Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics is supported by a stronger-than-expected Filspari franchise, with 2Q26 revenue of $141.1M and 2,012 new patient start forms, while physician survey data points to IgAN usage rising from 16% to 22% and FSGS from about 15% to 30% within six months. The recently issued Notice of Allowance for FSGS patent protection, expected to extend into October 2037 alongside the IgAN patent, materially improves exclusivity durability and reduces a key bear case around revenue erosion. With Bradley Campbell bringing more than 25 years of biopharma experience and a track record of scaling a rare disease business, the company gains added leadership depth as it advances pegtibatinase and other pipeline assets beyond Filspari.

Travere Therapeutics is facing a cautious outlook because, despite $489.2 million in cash, cash equivalents, and marketable securities at the end of 1Q 2026, its funding base may still require additional capital to support operations and portfolio advancement. The risk of a follow-on stock offering could dilute current shareholders, while any constraints in capital markets would make it harder to fund development and commercialization efforts. The company’s valuation also remains vulnerable to delays or setbacks in commercializing Filspari or pegtibatinase, which could materially reduce sales potential and undermine confidence in its pipeline.